Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ondansetron versus amantadine for fatigability in multiple sclerosis
IRCT20120215009014N250Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ondansetron and amantadine in multiple sclerosis (MS) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Assessing the fatigability. Started Nov 2018; status: completed.
02
Drugs
ondansetronamantadine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20120215009014N250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N250.